Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


Lyophilisation: Freeze-Drying in Pharmaceuticals and Biopharmaceuticals

25 Feb 2013 - 26 Feb 2013 - London, UK



Bookmark and Share


SMi is proud to present their inaugural conference on Lyophilisation: Freeze-drying in pharmaceuticals & Biopharmaceuticals, with key talks from Medimmune, GSK Biologicals, National Institute for Biological Standards & Control and Roche on the best practices, novel discoveries and industry innovations that are essential to the development of a company’s lyophilisation process. This conference is not to be missed as this is the forum for you to learn, explore and discover the cutting edge areas of the industry, and the essential ways a company can improve its freeze drying methods.

Benefits of attending include:                                                                         Learn of formulation techniques that assist in the lyophilisation process, and how to apply these to your own technical issues

·         Explore the latest research and development in the industry, and how these have led to improved lyophilisation cycles, both pre, and post up-scaling

·         Discover the potential technical and logistical difficulties encountered in all levels of the lyophilisation process

·         Consider the regulations in chemical engineering and how compliance can be achieved

·         Examine previous examples of up-scaling in the industry, and how to apply these to your own freeze-drying process

·         Hear about regulations, monitoring and risk reduction, to improve the cost effectiveness of the cycle, and how these can be used to manage risks and adapt to the problems encountered

Key speakers include:

 Yves Mayeresse, Director of Manufacturing, GSK Biologicals

·         Sajal Patel, Scientist II, MedImmune

·         Patrick Garidel, Head of Pharmaceutical Basic Development, Boehringer Ingelheim

·         Paul Matejtschuk, Principal Scientist, National Institute For Biological Standards & Control

Sune Klint Andersen, Principal Scientist Drying Processes, Novo Nordisk A/s          

       Jean René Authelin, Global Head of Pharmaceutical Engineering, Pharmaceutical Sciences, Sanofi R&D

·         Ahmad Abdul-Fattah, Group Leader, Late Stage Pharmaceutical and Processing Development, Roche

 Register at http://www.smi-online.co.uk/goto/lyophilisation-conference.asp

Or alternatively contact Annie Blundell on tel +44 (0)20 7827 6090 or email: ablundell@smi-online.co.uk



Further information
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!